- Home
- AQMS vs SNTI Comparison
AQMS vs SNTI Comparison
Compare AQMS & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQMS
- SNTI
- Stock Information
- Founded
- AQMS 2014
- SNTI 2016
- Country
- AQMS United States
- SNTI United States
- Employees
- AQMS N/A
- SNTI N/A
- Industry
- AQMS Metal Fabrications
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- AQMS Industrials
- SNTI Health Care
- Exchange
- AQMS Nasdaq
- SNTI Nasdaq
- Market Cap
- AQMS 17.8M
- SNTI 19.1M
- IPO Year
- AQMS 2015
- SNTI N/A
- Fundamental
- Price
- AQMS $1.98
- SNTI $4.67
- Analyst Decision
- AQMS Strong Buy
- SNTI Strong Buy
- Analyst Count
- AQMS 2
- SNTI 1
- Target Price
- AQMS $30.00
- SNTI $12.00
- AVG Volume (30 Days)
- AQMS 371.2K
- SNTI 115.8K
- Earning Date
- AQMS 11-14-2024
- SNTI 11-14-2024
- Dividend Yield
- AQMS N/A
- SNTI N/A
- EPS Growth
- AQMS N/A
- SNTI N/A
- EPS
- AQMS N/A
- SNTI N/A
- Revenue
- AQMS N/A
- SNTI N/A
- Revenue This Year
- AQMS N/A
- SNTI $11.52
- Revenue Next Year
- AQMS N/A
- SNTI $78.57
- P/E Ratio
- AQMS N/A
- SNTI N/A
- Revenue Growth
- AQMS 525.00
- SNTI N/A
- 52 Week Low
- AQMS $1.33
- SNTI $1.52
- 52 Week High
- AQMS $14.14
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- AQMS 41.02
- SNTI 56.65
- Support Level
- AQMS $1.92
- SNTI $3.72
- Resistance Level
- AQMS $2.14
- SNTI $4.93
- Average True Range (ATR)
- AQMS 0.28
- SNTI 0.46
- MACD
- AQMS -0.05
- SNTI 0.01
- Stochastic Oscillator
- AQMS 6.32
- SNTI 81.82
About AQMS Aqua Metals Inc.
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.